keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/28535081/advances-in-antidepressants-for-treating-post-stroke-depression
#1
Stefano Paolucci
Introduction Post-stroke depression (PSD) is a common and serious complication after stroke, occurring in nearly one third of stroke survivors, and affecting mortality rate, functional outcome, rehabilitation results and quality of life. However, in the common clinical practice only a minority of patients are properly treated. A relatively small number of scientific reports are available on clinical usefulness and safety of antidepressants (ADs) in PSD. Areas Covered This report provides an updated review about pharmacological state of art of PSD, including efficacy and safety of different drugs and their role on prevention, treatment and functional outcome...
May 23, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28533517/vortioxetine-reduces-bold-signal-during-performance-of-the-n-back-working-memory-task-a-randomised-neuroimaging-trial-in-remitted-depressed-patients-and-healthy-controls
#2
J Smith, M Browning, S Conen, R Smallman, J Buchbjerg, K G Larsen, C K Olsen, S R Christensen, G R Dawson, J F Deakin, P Hawkins, R Morris, G Goodwin, C J Harmer
Cognitive dysfunction is common in depression during both acute episodes and remission. Vortioxetine is a novel multimodal antidepressant that has improved cognitive function including executive function in depressed patients in randomised placebo-controlled clinical trials. However, it is unclear whether vortioxetine is able to target directly the neural circuitry implicated in the cognitive deficits in depression. Remitted depressed (n=48) and healthy volunteers (n=48) were randomised to receive 14 days treatment with 20 mg vortioxetine or placebo in a double-blind design...
May 23, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28531820/adverse-effects-and-treatment-satisfaction-among-online-users-of-four-antidepressants
#3
Shannon Hughes, Jeffrey Lacasse, Reid Rogers Fuller, Jennifer Spaulding-Givens
Adverse effects (AEs) are an important factor in antidepressant treatment decision-making, though common AE profiles from clinical trial research highlight physical AEs to the neglect of emotional and behavioral AEs. First-hand accounts of antidepressant users on the Internet can supplement AE profiles with information gained from real-world treatment experiences. We examined online user reviews of two older (escitalopram; duloxetine) and two newer (vilazodone; vortioxetine) antidepressants for differences in their AE profiles and determined which categories of AEs were associated with users' satisfaction...
May 16, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28499187/vortioxetine-a-review-of-the-pharmacology-and-clinical-profile-of-the-novel-antidepressant
#4
REVIEW
Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Rafał R Jaeschke, Katherine Sendek, Krzysztof Styczeń, Wojciech Datka, Magdalena Koperny
The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of vortioxetine. Vortioxetine is a novel antidepressant, approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). Because vortioxetine exhibits both an antidepressant and anxiolytic effect, it may be effective in treating both depressive and anxiety disorders, such as generalized anxiety disorder (GAD). Based on its pharmacodynamics profile and preclinical studies, it is believe that the drug's clinical action is mediated mainly by selective blockade of serotonin reuptake (by inhibiting the serotonin transporter [SERT]) and direct modulation of 5-HT receptors activity (such as 5-HT3, 5-HT7, 5-HT1D and 5-HT1B)...
February 1, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28414050/a-study-of-time-and-sex-dependent-effects-of-vortioxetine-on-rat-sexual-behavior-possible-roles-of-direct-receptor-modulation
#5
Yan Li, Alan L Pehrson, Ronald S Oosting, Maria Gulinello, Berend Olivier, Connie Sanchez
Treatment-related sexual dysfunction is a common side effect of antidepressants and contributes to patient non-compliance or treatment cessation. However, the multimodal antidepressant, vortioxetine, demonstrates low sexual side effects in depressed patients. To investigate the mechanisms involved, sexual behavior was assessed in male and female rats after acute, and repeated (7 and 14 days) treatment with vortioxetine, flesinoxan (a 5-HT1A receptor agonist), CP-94253 (a 5-HT1B receptor agonist), or ondansetron (a 5-HT3 receptor antagonist)...
April 13, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28408985/new-drugs-in-psychiatry-focus-on-new-pharmacological-targets
#6
REVIEW
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago
The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease...
2017: F1000Research
https://www.readbyqxmd.com/read/28407315/drugs-with-antidepressant-properties-affect-tryptophan-metabolites-differently-in-rodent-models-with-depression-like-behavior
#7
Amanda Eskelund, Yan Li, David P Budac, Heidi K Müller, Gulinello Maria, Connie Sanchez, Gregers Wegener
The metabolism of tryptophan through kynurenine and serotonin pathways is linked to depression. Here, effects of different drugs with antidepressant properties (vortioxetine, fluoxetine and ketamine) on various tryptophan metabolites in different brain regions and plasma were examined using tandem mass spectrometry (LC-MS/MS), in Flinders Sensitive Line (FSL) rats, a genetic rat model of depression, and its controls: Flinders Resistant Line (FRL) and Sprague-Dawley (SD) rats. Protein levels of kynurenine pathway enzymes were measured in the brains and livers of these rat strains...
April 13, 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/28366617/acute-dosing-of-vortioxetine-strengthens-event-related-brain-activity-associated-with-engagement-of-attention-and-cognitive-functioning-in-rats
#8
Bettina Laursen, Cecilie H Bundgaard, Carina Graversen, Morten Grupe, Connie Sanchez, Steven C Leiser, Helge B D Sorensen, Asbjørn M Drewes, Jesper F Bastlund
Studies of the antidepressant vortioxetine have demonstrated beneficial effects on cognitive dysfunction associated with depression. To elucidate how vortioxetine modulates neuronal activity during cognitive processing we investigated the effects of vortioxetine (3 and 10 mg/kg) in rats performing an auditory oddball (deviant target) task. We investigated neuronal activity in target vs non-target tone responses in vehicle-treated animals using electroencephalographic (EEG) recordings. Furthermore, we characterized task performance and EEG changes in target tone responses of vortioxetine vs controls...
March 30, 2017: Brain Research
https://www.readbyqxmd.com/read/28333546/pharmacokinetics-and-safety-of-vortioxetine-in-pediatric-patients
#9
Robert L Findling, Adelaide S Robb, Melissa DelBello, Michael Huss, Nora McNamara, Elias Sarkis, Russell Scheffer, Lis H Poulsen, Grace Chen, Ole Michael Lemming, Johan Areberg, Philippe Auby
OBJECTIVE: The primary objectives of this study were to evaluate the pharmacokinetics (PK) and tolerability of single and multiple doses of vortioxetine in children and adolescents with a depressive or anxiety disorder and to provide supportive information for appropriate dosing regimens for pediatric clinical trials. METHODS: This prospective, open-label, multinational, multisite, multiple-dose trial enrolled 48 patients (children and adolescents; 1:1 ratio) divided into 8 cohorts (4 adolescent and 4 child), with each cohort including 6 patients...
March 23, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28317392/pharmacotherapy-of-major-depression-in-late-life-what-is-the-role-of-new-agents
#10
REVIEW
Kinjal Patel, Petal S Abdool, Tarek K Rajji, Benoit H Mulsant
Evidence on the pharmacotherapy of late-life major depressive disorder (LLD) is scant. Most of the recommendations in existing clinical guidelines are based on expert opinions, extrapolations from data obtained in younger patients, or theoretical considerations. Areas covered: This article summarizes the recommendations from existing clinical guidelines and recent reviews on the treatment of LLD. Next, it discusses the potential role of newer antidepressants - vilazodone, levomilnacipran, and vortioxetine - based on a systematic search of the literature published during the past five years...
April 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28293465/the-effect-of-vortioxetine-on-overall-patient-functioning-in-patients-with-major-depressive-disorder
#11
Ioana Florea, Henrik Loft, Natalya Danchenko, Benoît Rive, Melanie Brignone, Elizabeth Merikle, Paula L Jacobsen, David V Sheehan
BACKGROUND: The objectives of this meta-analysis of data from randomized, placebo-controlled studies were to assess the effect of vortioxetine on overall functioning (primary) and functional remission (secondary) using the Sheehan Disability Scale (SDS) in adults with major depressive disorder (MDD). METHODS: Data from nine short-term (6/8 weeks) pivotal studies that included patient functioning assessments were included in this random-effects meta-analysis, which used aggregated study-level data for all therapeutic vortioxetine doses and a mixed-effect model for repeated measures using the full analysis set...
March 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28277865/the-impact-of-antidepressant-treatments-on-family-functioning-in-adults-with-major-depressive-disorder-a-post-hoc-comparison-of-vortioxetine-and-agomelatine
#12
Clément François, Rebecca Nielsen, Natalya Danchenko, Valerie Williams, Christophe Lançon
OBJECTIVE: There is limited research on the impact of antidepressant treatment on family functioning. This study examines the impact of vortioxetine and agomelatine on family functioning using the Depression and Family Functioning Scale (DFFS). METHODS: The DFFS was included in REVIVE, a randomized, double-blind study of adults with major depressive disorder with inadequate response to antidepressant treatment who switched to vortioxetine or agomelatine. The prespecified DFFS analyses were performed using change from baseline to weeks 8 and 12, analyzed by mixed models for repeated measurements by treatment groups...
June 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28272863/serotonin-transporter-independent-actions-of-the-antidepressant-vortioxetine-as-revealed-using-the-sert-met172-mouse
#13
Alex G Nackenoff, Linda D Simmler, Nicole L Baganz, Alan L Pehrson, Connie Sánchez, Randy D Blakely
Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter...
March 20, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28245753/methodological-differences-as-an-explanation-for-the-divergent-results-of-studies-on-sexual-dysfunction-related-to-the-use-of-vortioxetine
#14
Marrit K de Boer, Robert A Schoevers
No abstract text is available yet for this article.
March 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28213121/determination-of-a-clinically-important-difference-and-definition-of-a-responder-threshold-for-the-ucsd-performance-based-skills-assessment-upsa-in-patients-with-major-depressive-disorder
#15
Philip D Harvey, William Jacobson, Wei Zhong, George G Nomikos, Michael Cronquist Christensen, Christina Kurre Olsen, Elizabeth Merikle
BACKGROUND: This article reports an evaluation of the psychometric properties and clinically important difference (CID) threshold of the UCSD Performance-Based Skills Assessment (UPSA) in major depressive disorder (MDD), using data from a large-scale study of the effects of vortioxetine on cognitive functioning and functional capacity in MDD patients. METHODS: Adults with moderate-to-severe recurrent MDD and self-reported cognitive dysfunction were randomized to 8 weeks of double-blind treatment with vortioxetine 10/20mg QD (flexible), duloxetine 60mg QD, or placebo...
April 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28109109/-role-of-camp-creb-bdnf-signaling-pathway-in-anti-depressive-effect-of-vortioxetine-in-mice
#16
Hui Yu, Jia-Jia Chen, Bing-Qing Zeng, Qiu-Ping Zhong, Jiang-Ping Xu, Yong-Gang Liu
OBJECTIVE: To investigate the effects of vortioxetine on cAMP/CREB/BDNF signal pathway. METHODS: Forty Kunming mice were randomized into control group and chronic unpredictable mild stress (CUMS) group. After establishment of depressive models verified by sucrose preference test, the mice in CUMS group were divided into model group, fluoxetine group and vortioxetine group. The antidepressive effect of vortioxetine was analyzed by tail suspension test, forced swim test and open field test...
January 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28108062/chronic-vortioxetine-treatment-in-rodents-modulates-gene-expression-of-neurodevelopmental-and-plasticity-markers
#17
Jessica A Waller, Joseph A Tamm, Aicha Abdourahman, Alan L Pehrson, Yan Li, Manuel Cajina, Connie Sánchez
The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity...
February 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28007563/crystal-structures-x-ray-photoelectron-spectroscopy-thermodynamic-stabilities-and-improved-solubilities-of-2-hydrochloride-salts-of%C3%A2-vortioxetine
#18
Jing Li, Li-Yang Li, Sai-Fei He, Shan Li, Chang-Zhi Dong, Lei Zhang
Two vortioxetine (VOT) salts with hydrochloride (VOT-HCl and VOT-0.5HCl) were prepared and structurally characterized. VOT-HCl features 1-dimensional P/M helical chains through N-H···Cl hydrogen bond interactions, whereas VOT-0.5HCl possesses a 1-dimensional zigzag structure in which 2 VOT molecules share a single proton through N···H(+)···N interactions. VOT-HCl converts into the monohydrate VOT-HCl·H2O after dissolution in water, whereas VOT-0.5HCl remains stable. The N 1s X-ray photoelectron spectroscopy analysis shows a characteristic binding energy peak at approximately 398...
December 20, 2016: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27996982/-vortioxetine-in-the-treatment-of-major-depression
#19
Andrea de Bartolomeis, Andrea Fagiolini, Giuseppe Maina
Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity of major depressive disorder, few innovative medications have been developed in recent years for the treatment of this heterogeneous disease. Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. A recent meta-analysis of 11 randomized, double-blind, placebo controlled, acute (6-8 weeks) treatment studies has demonstrated the efficacy of vortioxetine 5-20 mg/day in the treatment of depression, with an increasing effect associated with increasing dose...
November 2016: Rivista di Psichiatria
https://www.readbyqxmd.com/read/27972892/cost-utility-analysis-evaluating-vortioxetine-versus-venlafaxine-xr-and-agomelatine-in-the-treatment-of-major-depressive-disorder-in-taiwan
#20
M Brignone, K Atsou, C Reynaud-Mougin, W Chen, D Milea
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"